(NYSE: RCUS) Arcus Biosciences's forecast annual revenue growth rate of -10.25% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 101.87%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.74%.
Arcus Biosciences's revenue in 2025 is $240,000,000.On average, 13 Wall Street analysts forecast RCUS's revenue for 2025 to be $26,223,532,688, with the lowest RCUS revenue forecast at $24,231,420,949, and the highest RCUS revenue forecast at $28,796,542,051. On average, 13 Wall Street analysts forecast RCUS's revenue for 2026 to be $15,418,620,941, with the lowest RCUS revenue forecast at $3,915,120,415, and the highest RCUS revenue forecast at $27,317,304,608.
In 2027, RCUS is forecast to generate $21,795,537,977 in revenue, with the lowest revenue forecast at $10,708,383,406 and the highest revenue forecast at $37,258,428,068.